What's Happening?
Zepto Life Technology has announced that its FungiFlex Mold Panel, a liquid biopsy test, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This test is designed to aid in diagnosing invasive mold infections
by detecting and identifying fungal cell-free DNA directly from plasma. The FungiFlex Mold Panel is available for physician ordering through Zepto Life Technology's CLIA-certified laboratory as a Laboratory Developed Test (LDT). It targets clinically relevant mold pathogens such as Aspergillus, Mucorales, Fusarium, and Scedosporium/Lomentospora. The test aims to provide organism-level identification directly from plasma, addressing significant limitations of current diagnostic approaches.
Why It's Important?
The FDA's Breakthrough Device Designation is significant as it highlights the potential of the FungiFlex Mold Panel to address a critical unmet need in diagnosing invasive mold infections. These infections are particularly challenging to diagnose and are associated with high morbidity and mortality rates, especially in immunocompromised patients. Current diagnostic methods require a combination of imaging, microbiology, histopathology, and serologic testing, yet often fail to provide organism-level identification. The FungiFlex Mold Panel could revolutionize the diagnostic process by offering precise organism-level information from a simple plasma sample, potentially leading to more effective and timely treatment decisions.
What's Next?
With the Breakthrough Device Designation, Zepto Life Technology is positioned to accelerate the development and availability of the FungiFlex Mold Panel. The designation is part of the FDA's program to expedite the development of technologies that may provide more effective diagnosis or treatment of life-threatening diseases. As the company continues to develop its targeted liquid biopsy diagnostics, it may seek further collaborations and partnerships to expand the reach and application of its technology. The success of the FungiFlex Mold Panel could pave the way for similar diagnostic advancements in other infectious diseases.
